Sort
10,766 grants matching “checkpoint inhibitor”
Center for Lupus Research
$1,499,729Maria Virginia Pascual · Baylor Research Institute · P50 · FY2007 · AR
Clinical and Mechanistic Investigations of Salivary Gland Dysfunction
$1,499,358Blake Warner · National Institute Of Dental & Craniofacial Research · ZIA · FY2021 · DE
SBIR Topic 354: A Novel Predictive Test for Response to Combination Immunotherapies for Patients with non-small cell lung cancer (NSCLC)
$1,498,027Greg Bertenshaw · Biomarker Strategies, Llc · N44 · FY2019 · CA
Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer
$1,497,616Howard C Crawford · University Of Michigan At Ann Arbor · U01 · FY2017 · CA
2/2 CCNY-MSKCC Partnership for Cancer Research, Education and Community Outreach
$1,496,000Francesca M Gany · Sloan-Kettering Inst Can Research · U54 · FY2025 · CA
2/2 CCNY-MSKCC Partnership for Cancer Research, Education and Community Outreach
$1,496,000Tim Alan Ahles · Sloan-Kettering Inst Can Research · U54 · FY2024 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$1,495,060Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models
$1,495,060Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Novel Targets for Immunotherapy
$1,493,975Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Therapeutic vaccination and PD-1 blockade in treated HIV disease
$1,491,834Steven Grant Deeks · University Of California, San Francisco · U01 · FY2017 · AI
CD28-KITv CAR T cells with PD-1 dominant negative receptor
$1,491,519Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · UG3 · FY2024 · CA
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer
$1,485,601Angelo Michael De Marzo · Johns Hopkins University · U54 · FY2023 · CA
Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies
$1,484,033Anish Thomas · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Strategies for Cancer Immunotherapy Development: Preclinical Studies
$1,477,304Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Strategies for Cancer Immunotherapy Development: Preclinical Studies
$1,477,130Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
$1,473,606Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2023 · CA
IDENTIFYING BIOMARKERS AND DISSECTING COMBINATORIAL SYNERGIES TO IMPROVE IMMUNE CHECKPOINT INHIBITOR RESPONSE IN BLADDER CANCER
$1,472,880The Cleveland Clinic Foundation · · FY2020 · Defense Health Agency
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC
$1,471,018Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Mechanisms of Nucleic Acid Enzymes - Pol Beta and Mammalian Base Repair Enzymes
$1,468,712Samuel H Wilson · Environmental Health Sciences · Z01 · FY2007 · ES
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes
$1,468,055Brigitte Widemann · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Cellular Interactions with Thrombospondin
$1,467,128David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2022 · CA
Studies of the Function of Naturally Occurring and Adaptive T Regulatory Cells
$1,465,468Ethan Shevach · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
$1,463,720David E Fisher · Massachusetts General Hospital · P01 · FY2020 · CA
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,461,857Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2022 · CA
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
$1,461,713David E Fisher · Massachusetts General Hospital · P01 · FY2021 · CA